Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present data at the American Diabetes Association 79th Scientific Sessions in San Francisco (June 7-11, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in clinical development for Diabetic Cardiomyopathy (DbCM). The Late Breaking Science poster, entitled “Phase 1/2 Safety and Proof of Biological Activity Study of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy” highlights a recently completed Phase 1/2 study in approximately 120 patients with type 2 diabetes, a subset of which had DbCM.
“Diabetic complications, such as Diabetic Cardiomyopathy, continue to grow despite advancements in glucose control. It’s imperative that therapies are developed to treat or prevent diabetic complications through mechanisms other than glycemic modification,” said Riccardo Perfetti, MD, PhD. “We are excited to be presenting our data at the prominent ‘Late Breaking’ session at ADA, and are thrilled by the recognition from the congress and the clinical community. Targeting aldose reductase with a potent and selective inhibitor presents an opportunity to potentially halt disease progression and prevent worsening of heart failure in DbCM patients. We look forward to initiating our pivotal program for AT-001 in DbCM later this year.”
Phase 1/2 Safety and Proof of Biological Activity Study of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy
(Late Breaking Abstract – oral poster presentation Sunday, June 9, 12-1pm)
(Late Breaking Abstract – oral poster presentation Sunday, June 9, 12-1pm)
- AT-001 was well tolerated at all doses tested
- Target engagement was confirmed by potent aldose reductase (AR) inhibition as evidenced by significant reductions in sorbitol, a pharmacodynamic biomarker of AR activity
- AT-001 improved selectivity and affinity for AR resulted in potent AR inhibition
About Diabetic Cardiomyopathy
Diabetic Cardiomyopathy (DbCM) is a rapidly progressing degenerative disorder of the heart muscle in people with diabetes. There are no approved therapies for this fatal condition, which affects 17 – 24 percent of people with diabetes, or approximately 77 million patients worldwide. Hyperglycemia, a symptom that characterizes diabetes, triggers the enzyme Aldose Reductase to convert excess glucose into sorbitol and fructose, both of which can lead to cell death in the heart muscle. When this happens, the heart fibroses, or “hardens,” such that the organ is unable to circulate blood through the body effectively. Approximately 25 percent of patients with DbCM progress to overt heart failure or death within 1.5 years of diagnosis.
Diabetic Cardiomyopathy (DbCM) is a rapidly progressing degenerative disorder of the heart muscle in people with diabetes. There are no approved therapies for this fatal condition, which affects 17 – 24 percent of people with diabetes, or approximately 77 million patients worldwide. Hyperglycemia, a symptom that characterizes diabetes, triggers the enzyme Aldose Reductase to convert excess glucose into sorbitol and fructose, both of which can lead to cell death in the heart muscle. When this happens, the heart fibroses, or “hardens,” such that the organ is unable to circulate blood through the body effectively. Approximately 25 percent of patients with DbCM progress to overt heart failure or death within 1.5 years of diagnosis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.